NEXMED INC (WKN: 914164 / NEXM) / Nasdaq

HOMEPAGE:
http://www.nexmed.com/index.php

SEC-FILINGS:
http://www.sec.gov/cgi-bin/...e=&SIC=&owner=include&action=getcompany

NEWS/INFO's:
http://www.finanznachrichten.de/nachrichten-aktien/nexmed.asp
http://finance.yahoo.com/q?s=nexm
http://www.nexmed.com/investors/annualReport.php

BÖRSENPLÄTZE:
http://www.ariva.de/quote/simple.m?secu=5340

**************************************************

letzter Quartalsbericht:
http://www.sec.gov/Archives/edgar/data/1017491/...244/v131191_10q.htm

**************************************************

BUSINESS:
NexMed, Inc., a pharmaceutical and medical technology company, engages in the development of transdermal products based on its proprietary NexACT drug delivery technology. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin and enabling concentrations of the active drug to penetrate the desired site of the skin or extremity. The company�s products under development include NM100060, a nail lacquer treatment for onychomycosis; Femprox, which is an alprostadil-based cream product intended for the treatment of female sexual arousal disorder; and ED Product, which is an alprostadil-based cream treatment intended for patients with erectile dysfunction. It has a licensing agreement with Novartis International Pharmaceutical, Ltd. for the development, manufacture, and commercialization of NM100060. The company was founded in 1987 and is based in East Windsor, New Jersey. NexMed Inc. operates as a subsidiary of Alphatec Spine, Inc.

finance.yahoo.com/q?s=NEXM

PS: Hoffnung auf heutige NEWS (Kontrakt-Verlängerung) mit/durch www.wcrx.com/

(siehe auch: finance.google.ca/finance?q=NASDAQ:NEXM )

www.sec.gov/Archives/edgar/data/1017491/...1715/v136996_8k.htm

...
On January 12, 2009, NexMed, Inc. (the “Company”) and Warner Chilcott Company, Inc. (“Warner”) entered into an amendment (the “Amendment”) to the exclusive United States licensing agreement dated November 1, 2007, as amended by amendment entered into on November 24, 2008, by and between the Company and Warner (as amended, the “Agreement”), for NexMed’s proprietary topical alprostadil-based cream treatment for erectile dysfunction (“Vitaros®”).

Pursuant to the Amendment, Warner has been granted an additional 20 days, or until February 2, 2009, to review the results of the October 15, 2008 meeting (the “Meeting”) with the Food and Drug Administration (FDA).  The purpose of the Meeting was to gain clarification on the major deficiencies cited by the FDA in their July 21, 2008 action letter regarding the New Drug Application (NDA) for Vitaros®.  As such, on or before February 2, 2009, Warner must decide whether or not it wishes to continue with the development of Vitaros®.  If Warner decides that it does not wish to continue with Vitaros® then the Agreement would terminate and all rights would revert back to the Company.  Warner was previously granted an additional 45 days, or until January 13, 2009, to review such regulatory concerns.

da geht was

According to IMS data, the U.S. ED market in 2007 was about $1.5 billion -- dominated by oral PDE5 treatments. Despite the availability of today's oral and other therapies, there is still a need for new, safe and effective treatments, especially for those patients who cannot or do not respond well to oral medication. Alprostadil, well-recognized as a safe and effective drug for the treatment of ED, is currently marketed as both an injectable and intra-urethral pellet. NexMed's topical product provides a more patient-friendly alternative due to its non-invasive ease of administration.

About Warner Chilcott

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. (WCRX-G)

Read more on www.warnerchilcott.com.

About NexMed

NexMed, Inc. leverages its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NexMed's novel onychomycosis treatment is licensed to Novartis for global development. NexMed's pipeline also includes a Phase 2 treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Read more on www.nexmed.com

Warner Chilcott's Forward-Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, economic performance, financial condition, business plans, growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2007; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

NexMed's Forward Looking Statements:

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of NexMed, Inc.

NexMed management will host a conference call and provide an investor update today, Tuesday, February 3, 2009 at 10:00am EST. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 312198 are both required for playback. The conference call will also be Webcast live at URL http://www.investorcalendar.com/IC/CEPage.asp?ID=140732. The Webcast replay will be available for three months.

About NexMed:

NexMed, Inc. leverages its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NexMed’s novel onychomycosis treatment is licensed to Novartis for global development. NexMed’s pipeline also includes its late stage alprostadil treatment for erectile dysfunction, licensed to Warner Chilcott, a Phase 2 treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Forward Looking Statements:

During the course of the call, NexMed Management will make forward looking statements regarding future events or the future financial performance of the Company that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, generating positive clinical results, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company. Such statements are predictions based on current expectations and actual results could differ materially.

Contacts:

NexMed, Inc.
Mark Westgate, CFO, 609-371-8123, ext: 159
mwestgate@nexmed.com
or
Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

http://www.finanznachrichten.de/...io-ceo-investor-conference-004.htm

03.02.2009 19:17
NexMed to Present at the 11th Annual BIO CEO & Investor Conference

NexMed, (News) Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® drug delivery technology, today announced that Vivian Liu, Chief Executive Officer, will present an overview of the company at the BIO CEO&Investor Conference on Tuesday, February 10, 2009 at 11 am (ET) at the Waldorf Astoria Hotel in New York City.

BIO CEO is the largest independent investor conference focused on leading publicly traded biotech companies, and is designed to appeal to public market investors as well as the sell-side investment community, in addition to business development executives from global pharmaceutical and biotechnology companies.

Interested parties may access the live webcast of NexMed’s presentation on the Company’s website (Investors: News&Events) at http://www.nexmed.com.

About NexMed

NexMed, Inc. leverages its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NexMed’s novel onychomycosis treatment is licensed to Novartis for global development. NexMed’s pipeline also includes its late stage alprostadil treatment for erectile dysfunction, a Phase 2 treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Contacts:

NexMed, Inc.
Mark Westgate, CFO
609-371-8123, ext: 159
mwestgate@nexmed.com
or
Investor Relations:
Rx Communications Group, LLC
Paula Schwartz
917-322-2216
pschwartz@rxir.com

www.finanznachrichten.de/...q-delisting-warning-letter-004.htm

24.03.2009 21:16
NexMed Receives Nasdaq Delisting Warning Letter

NexMed, (News) Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on the Company’s proprietary NexACT® drug delivery technology, today announced that it has received a notice from Nasdaq indicating that it does not comply with the minimum $2.5 million in stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Marketplace Rule 4310(c)(3). Additionally, the Company does not comply with the alternative Marketplace Rule which requires total market value of listed securities of $35 million or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. Further, the company remains on notice for maintaining the minimum $1 bid requirement as set forth in Marketplace Rule 4310(c)(8)(D). However, because Nasdaq has suspended enforcement of this requirement until July 20, 2009, as of its announcement on March 23, 2009, the Company now has until January 9, 2010 to meet that requirement.

...(weiter siehe LINK)

ih.advfn.com/...id=staticchart&s=N%5ENEXM&p=0&t=2" style="max-width:560px" />

EAST WINDSOR, NJ - (Business Wire) NexMed, Inc. (Nasdaq: NEXM), a developer of innovative topical products based on the NexACT ® technology, today announced that it has received a notice from Nasdaq indicating that it does not comply with the minimum $2.5 million in stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Marketplace Rule 4310(c)(3). East Windsor, NJ - (BUSINESS WIRE) NexMed, Inc. (Nasdaq: NEXM), ein Entwickler von innovativen topischen Produkten auf der Grundlage der NexACT ®-Technologie, gab heute bekannt, dass sie erhalten hat, eine Mitteilung Nasdaq dem hervorgeht, dass es nicht im Einklang mit den mindestens 2,5 Millionen US $ in das Eigenkapital Voraussetzung für die weitere Notierung an der NASDAQ Capital Market, die in Artikel Marktplatz 4310 (c) (3). As of June 30, 2009, the date of the Company's most recently filed financial statements, the Company's total stockholders' equity was $1,700,553. As of June 30, 2009, dem Datum der Gesellschaft zuletzt eingereichten Abschlüsse, die der Gesellschaft insgesam

sicherlich nicht erreicht werden wird/kann, wird es zum Delisting kommen.
Dies wird natürlich (negativ) den Kurs beeinflussen, jedoch am Unternehmen selber hat sich nichts verändert...

****
Nasdaq will provide written notice that the Company’s common stock will be delisted from the Nasdaq National Market at the opening of business on August 27, 2009

NexMed Receives Nasdaq Delisting Warning Letter

Date : 08/14/2009 @ 12:45PM
Source : Business Wire
ih.advfn.com/...0268785&article=39055611&symbol=N^NEXM

www.finanznachrichten.de/...-compliance-plan-to-nasdaq-004.htm

27.08.2009 16:05
NexMed Submits Compliance Plan to Nasdaq

NexMed, Inc. (Nasdaq: NEXM), a developer of innovative topical products based on the NexACT® technology, today announced that it has submitted to Nasdaq its plan to achieve and sustain compliance with Marketplace Rule 4310(c)(3). The plan will be reviewed by Nasdaq and, if deemed to be acceptable, the Company would be granted up to 105 calendar days from the date of Nasdaq’s notice to the company, or November 25, 2009, to evidence compliance with Marketplace Rule 4310(c)(3).

On August 14, 2009, the Company announced that it had received a notice from Nasdaq indicating that it did not comply with the minimum $2.5 million in stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Marketplace Rule 4310(c)(3). There can be no assurance that Nasdaq’s Listing Qualifications Panel will decide to allow the Company to remain listed. If the Company’s plan is not acceptable to Nasdaq, then the Company will be notified of its delisting. The Company also remains on notice for maintaining the minimum $1 bid requirement as set forth in Marketplace Rule 4310(c)(8)(D). However, because Nasdaq had suspended enforcement of this requirement until August 3, 2009, as of its most recent announcement on July 13, 2009, the Company now has until January 25, 2010 to meet that requirement.

...(weiter siehe LINK)

NexMed, Inc. to Acquire Bio-Quant, Inc.

Date : 11/23/2009 @ 8:00AM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)

ih.advfn.com/...8982157&article=40471999&symbol=N^NEXM

NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Upon closing of the transaction, which is expected before the end of the year, Bio-Quant will become a wholly-owned subsidiary of NexMed. Bassam Damaj, Ph.D., co-founder, current Chief Executive Officer and Chief Scientific Officer of Bio-Quant, will become Chief Executive Officer of NexMed, replacing Vivian Liu, who will transition to the role of Executive Vice President and, in that capacity, Ms. Liu will continue to be responsible for leading the business development and licensing efforts for NexMed’s clinical programs. Mark Westgate will remain as NexMed’s Chief Financial Officer. The Board will be composed of three Bio-Quant nominees and four NexMed nominees, and Ms. Liu is expected to be appointed as Chairman of the Board.

The agreement provides for NexMed’s issuance of 4,000,000 unregistered shares of its common stock to the Bio-Quant shareholders and a promissory note (the “Note”) in the amount of approximately $12.1 million due on December 31, 2010. NexMed can elect to pay all or any portion of the Note by issuing its common stock. Such repayment in common stock is contingent upon NexMed shareholder approval. As a condition to closing, there will be a Bio-Quant shareholders meeting. Certain key shareholders of Bio-Quant have agreed to vote in favor of the transaction.

Commenting on today’s news, Ms. Liu stated, “We look forward to welcoming the Bio-Quant team as a NexMed subsidiary. Through this transaction, NexMed acquires a revenue generating, cash flow positive business which has grown over 250% in the past five years and is continuing to grow at present. Moreover, we will gain preclinical capabilities, add valuable licensing expertise and be able to leverage Bio-Quant’s existing relationships with key pharmaceutical companies – all of which will aid in the continued development and the ultimate commercialization of our products under development.”

Dr. Damaj, noted, “We are delighted to become part of NexMed, a company with a novel technology and innovative products which we believe can be better monetized and generate value for our shareholders. While continuing our normal course of business as a leading CRO, we will be adding Our established and growing business, resources, and expertise to NexMed, which should allow NexMed to continue its business development in a more rapid and efficient manner.”

Mark Westgate added, “The acquisition of Bio-Quant was an integral part of our compliance plan presented to the NASDAQ Listing Qualification Panel (the “Panel”) on Thursday, November 12, 2009. We are hopeful that the signing of this agreement will give the Panel further confidence that we will regain and maintain compliance with all applicable continued listing requirements. While we have yet to receive a decision from the Panel, we are optimistic that the Panel will continue our listing pending the implementation of our plan.”

FTN Equity Capital Markets Corp., in New York City, has served as NexMed’s financial advisor in the structuring and negotiations of this transaction.

Conference Call

The Company will hold a conference call to discuss this announcement, today, Monday, November 23, 2009 at 9:00 am EST. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 338281 are both required for playback. The conference call will also be Webcast live at URL www.investorcalendar.com/IC/CEPage.asp?ID=152583. The Webcast replay will be available for three months.

About NexMed

NexMed’s pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information, go to www.nexmed.com.

About Bio-Quant

Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes. For further information, go to www.bio-quant.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, maintaining NexMed’s listing on NASDAQ, closing of the Bio-Quant acquisition, entering into licensing agreements for products under development, obtaining regulatory approval for its products under development, entering into a strategic transaction for the company, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.

NexMed Receives Cash Infusion of $750,000

Date :     11/11/2009 @ 8:30AM
Source :     Business Wire
Stock :     NexMed, Inc. (NEXM)

ih.advfn.com/p.php

 NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on the NexACT® drug delivery technology, today announced that it raised $750,000 in gross proceeds from the issuance of new convertible notes due December 31, 2011 (the “Notes”), which are secured by a mortgage on NexMed’s facility in East Windsor, New Jersey. The Notes were purchased by two investors, including The Tail Wind Fund Ltd., a long term investor in NexMed.

The Notes are convertible into shares of NexMed common stock at $2 per share with a coupon rate of 7% per annum. The shares underlying the Notes will not be registered with the Securities and Exchange Commission.

About NexMed

NexMed’s pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a P 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

 

 

ih.advfn.com/...p;s=N%5ENEXM&p=0&t=20&showctype=1" style="max-width:560px" alt="" />

14.12.2009 21:55
www.finanznachrichten.de/...s-acquisition-of-bio-quant-004.htm

NexMed Closes Acquisition of Bio-Quant

Acquisition May Enable Continued NASDAQ Listing

Conference Call to Be Held at 3:30 pm EST Tomorrow

NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® technology, today announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Upon closing, Bio-Quant became a wholly-owned subsidiary of NexMed. Bassam Damaj, Ph.D., co-founder and former Chief Executive Officer and Chief Scientific Officer of Bio-Quant, was named President and Chief Executive Officer of NexMed, replacing Vivian Liu, who has assumed the role of Executive Vice President and was appointed Chairman of the Board of Directors. The Board of Directors is now composed of three Bio-Quant nominees and four NexMed nominees.

Commenting on today's news, Dr. Damaj stated, "The synergistic combination of NexMed's novel NexACT® technology and existing clinical assets with Bio-Quant's revenue generating business, will enable us to offer both our existing and potential pharmaceutical customers a broader array of products and services. I look forward to working closely with Vivian on our integration efforts, as well as on business development and licensing activities for NexMed's product pipeline."

Mark Westgate, Chief Financial Officer of NexMed, added, "The acquisition of Bio-Quant was an integral part of our compliance plan which we presented during our November 12, 2009 meeting with the NASDAQ Listing Qualification Panel. We remain hopeful that the closing of this transaction will give the NASDAQ Panel sufficient confidence in NexMed's ability to regain and maintain compliance with all applicable listing requirements going forward."

Conference Call

The Company will hold a conference call to discuss the closing of the Bio-Quant acquisition tomorrow, Tuesday, December 15, 2009 at 3:30 pm EST. The call can be accessed in the U.S. by dialing 877-407-0778 and outside of the U.S. by dialing 201-689-8565 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week in the U.S. by dialing 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 339648 are both required for playback. The conference call will also be Webcast live at URL www.investorcalendar.com/IC/CEPage.asp?ID=153616. The Webcast replay will be available for three months.

About NexMed

NexMed's pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information, go to www.nexmed.com.

About Bio-Quant

Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes. For further information, go to www.bio-quant.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, maintaining NexMed's listing on NASDAQ, entering into licensing agreements for products under development, obtaining regulatory approval for its products under development, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.

Contacts:

NexMed, Inc.
Mark Westgate, CFO, 609-371-8123, ext: 159
mwestgate@nexmed.com
or
NexMed, Inc.
Edward M. Cox, 858-222-8041
V.P. Investor Relations& Corporate Development
ecox@bio-quant.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


© 2009 Business Wire

18.12.2009 15:03
www.finanznachrichten.de/...ontinued-listing-on-nasdaq-004.htm

NexMed Granted Continued Listing on NASDAQ

NexMed must evidence minimum stockholders' equity of $2.5 million or minimum market capitalization of $35 million by March 31, 2010

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today announced that it received a letter from the NASDAQ Listing Qualifications Panel (the "Panel") on December 17, 2009, informing the Company that the Panel had granted the Company's request to remain listed on the NASDAQ Stock Market, subject to the condition that, on or before March 31, 2010, the Company evidence stockholders' equity of at least $2.5 million or a market value of listed securities of at least $35 million, which are the applicable minimum requirements for the continued listing of the Company's securities on The NASDAQ Capital Market.

The Panel's determination follows the Company's hearing before the Panel on November 12, 2009, at which the Panel considered the Company's plan to regain compliance with the continued listing requirements, including through the recent acquisition of Bio-Quant, Inc. While the Company is working to satisfy the requirements set forth in the Panel's decision, there can be no assurance that it will be able to do so.

Separately, and as previously announced, the Company remains subject to a grace period through January 25, 2010 to evidence compliance with the $1.00 bid price requirement for continued listing on NASDAQ. If at any time during the grace period the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Company will have evidenced compliance with the minimum bid price requirement. In the event it does not evidence compliance with the bid price requirement by January 25, 2010, the Company expects that it will be provided with formal notice of the deficiency and an opportunity to request an extension from the Panel to evidence compliance with the minimum bid price requirement.

About NexMed

NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization ("CRO") based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed is also developing a proprietary product pipeline based on its NexACT® drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information, go to www.nexmed.com and www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to the Company's ability to satisfy NASDAQ continued listing standards, and other matters that are outside the control of the Company.

Contacts:

NexMed, Inc.
Mark Westgate, CFO, 609-371-8123, ext: 159
mwestgate@nexmed.com
or
Edward Cox, 858-222-8041
V.P. Investor Relations&Corporate Development
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


© 2009 Business Wire

NexMed Provides Corporate Update
 
Date : 01/08/2010 @ 12:00PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
 
http://ih.advfn.com/...2970500&article=41031116&symbol=N^NEXM
 
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing
 
Product Pipeline Topical Alprostadil Treatments NexMed expects to hear from Health Canada concerning the approvability of its New Drug Submission (NDS) for Vitaros®, its topical treatment for erectile dysfunction, sometime in February 2010. As such, management has postponed negotiations with its potential partner until an approval decision from Health Canada is received, as partnering negotiations with a marketing approval would be expected to yield more favorable terms for the Company
 
In the U.S., NexMed is awaiting a response from the Food and Drug Administration (FDA) regarding the carcinogenicity (CAC) assessment package, which it expects to occur within the next two months. Partnering efforts for Femprox®, NexMed’s topical treatment for female sexual dysfunction, are on hold pending the final decision by the FDA
 
Outside of North America, NexMed is awaiting Health Canada or the FDA’s response to accelerate partnering efforts and/or filing for marketing approvals. To date, NexMed has received multiple indications of interest from international pharmaceutical companies that might be interested in partnering with NexMed
 
In addition, through its Bio-Quant research and development team, NexMed is running new efficacy studies on the Vitaros formulation to assess the potential of the compound for other indications such as wound healing and Raynaud’s Syndrome. NexMed’s strategy is to take advantage of the development work already completed for Vitaros and bolster the existing database with new data and apply it to potentially shorten the path of approval. The goal includes commencing partnering discussions in mid-2010 for the new indications, if the pre-clinical data are positive
 
NM100060 Onychomycosis Treatment NexMed is actively engaged in efforts to re-license this product for the treatment of nail fungus. In the meantime, Novartis continues to transfer the clinical and regulatory dossiers to the Company and the data are being shared with potential partners
 
Topical Psoriasis Treatment NexMed’s Bio-Quant R&D team is also proceeding with extensive pre-clinical efficacy studies to strengthen its psoriasis candidate while actively engaging in partnering discussions
 
Topical NSAID Program NexMed is also exploring the opportunity to license an early stage NSAID program, which includes an issued U.S. patent. This program was not pursued when NexMed chose to focus its resources on its sexual dysfunction programs. Preclinical data of the NexACT-based ketoprofen cream has shown more rapid and efficient delivery of the drug as compared to the currently marketed products
 
NexACT technology, Partnering as a Service NexMed has initiated discussions with potential partners regarding the application of its NexACT technology to drugs that will soon be going off-patent to help create a second-generation drug that has patent protection through the mechanism of delivery. The NexACT platform technology has demonstrated the potential to improve the topical absorption of active therapeutic ingredients and/or to develop new patient-friendlier routes of administration. Incorporating older drugs with the NexACT proprietary delivery system can create new products that not only provide patients with added therapeutic benefits, but can also extend the product life for up to an additional 20 years. As such, the Company intends to aggressively pursue these types of potential partnering arrangements going forward
 
NexACT technology, New Applications In addition to developing innovative topical treatments, NexMed’s new scientific team is evaluating the ability of the NexACT technology to deliver biologics, such as humanized or fully human antibodies, via transdermal application. The delivery of such biologics through the skin represents a novel approach to delivering antibodies to specific areas of the body with limited systemic exposure – potentially reducing side effects and toxicity. We are also evaluating the ability of the NexACT technology to deliver drugs orally, including various first-line oral chemotherapeutics, which currently have poor bioavailability and thus require high doses and result in certain toxic side effects
 
NASDAQ Listing On January 4, 2010, NexMed received an expected notice of non-compliance from The NASDAQ Stock Market LLC based upon its failure to solicit proxies and hold an annual meeting for fiscal 2008 by December 31, 2009, as required by NASDAQ Listing Rules 5620(a) and 5620(b), which could serve as an additional basis for the delisting of the Company’s securities from The NASDAQ Capital Market. NexMed had discussed this matter with the NASDAQ Listing Qualifications Panel (the “Panel”) at the hearing on November 12, 2009, and explained that it planned to postpone the 2008 annual meeting due to the ongoing acquisition of Bio-Quant and would not be able to incorporate all of the relevant acquisition related materials in the meeting proxy in a timely manner
 
As NexMed previously announced on December 18, 2009, the Panel granted its request to remain listed on The NASDAQ Capital Market, subject to the condition that it evidence stockholders’ equity of at least $2.5 million or a market value of listed securities of at least $35 million on or before March 31, 2010. The determination followed the hearing before the Panel on November 12, 2009, at which time NexMed presented its plan to evidence compliance with all requirements for continued listing on The NASDAQ Capital Market, including the proxy solicitation/annual meeting and bid price requirements (notwithstanding the fact that NexMed was not yet deficient with respect to those standards)
 
As provided by NASDAQ’s most recent notice, NexMed plans to timely make a formal written submission to the Panel presenting its plan to evidence compliance with the proxy solicitation and annual meeting requirements. While it intends to file a proxy statement for a special meeting of shareholders to be held within the next sixty days to consider amending its Articles of Incorporation to authorize more common stock for issuance, that meeting may not be conducted as an annual meeting since the proxy statement will not incorporate audited financial statements for the fiscal year ended December 31, 2009. As a result, in order to satisfy NASDAQ’s annual meeting requirement, NexMed plans to file a proxy statement for a joint 2008/2009 annual meeting promptly following the filing of its Annual Report on Form 10-K for fiscal 2009 in March 2010. Accordingly, the Company is asking the Panel to modify its previously issued decision in accordance with the Company’s revised plan of compliance. However, there can be no assurance that the Panel will grant the Company’s request
 
Also as previously announced, NexMed remains subject to a grace period through January 25, 2010 to evidence compliance with the $1.00 bid price requirement for continued listing on NASDAQ. In the event NexMed does not evidence compliance with the bid price requirement by that date, NexMed expects to receive an additional formal notice of non-compliance and to be afforded an opportunity to request an exception from the Panel to evidence compliance with the minimum bid price requirement. In that regard, NexMed will implement a reverse stock split, if necessary, to evidence compliance with NASDAQ’s minimum bid price requirement, which action may be taken at any time at the discretion of the NexMed Board of Directors
 
Corporate Integration Subsequent to the December 17, 2009 announcement of the lease of its manufacturing building in New Jersey, NexMed has completed the relocation of its headquarters to 6330 Nancy Ridge Drive, San Diego, CA 92121. NexMed now has 34 full time employees, of whom eight employees hold either Ph.D or MD degrees. NexMed will include the pro forma financial statements for the combined entity in an amendment to its December 17, 2009 Current Report on Form 8-K, to be filed on or before February 26, 2010
 
About NexMed NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization (“CRO”) based in San Diego, CA and is one of the industry’s most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed has a proprietary product pipeline based on its NexACT drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information, go to www.nexmed.com and www.bio-quant.com

Ich habe mich gestern aus Spaß bei Nexmed eingekauft. Jetzt sieht es im Pretrade ganz gut aus. Hat jemand neue News ich habe nichts gefunden. Wenn nämlich keine News sind würde ich sie heute gerne wieder abstoßen. lg

NexMed Announces the Ability of the NexACT® Technology to Deliver Drugs Orally and with Enhanced Bioavailability
 
Date : 01/12/2010 @ 1:51PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
 
http://ih.advfn.com/...pid=nmona&article=41075942&symbol=NEXM
 
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete
 
Dr. Bassam Damaj, NexMed’s Chief Executive Officer stated, “The results from these proof of concept studies are exciting and support our belief that NexACT can be successfully used to enhance oral bioavailability of a broad range of drugs, which could include our proprietary drug candidates, generic drugs and proprietary drugs owned by others who are developing second-generation formulations to provide extended patent protection with increased convenience and bioavailability. Our ability to leverage our proprietary NexACT technology in this way is expected to provide exciting new development opportunities and will no longer restrict us to the topical delivery of dermal drugs. Additional studies are ongoing to extend the validation of the technology into other classes of oral drugs.” About NexMed NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization (“CRO”) based in San Diego, CA and is one of the industry’s most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed has a proprietary product pipeline based on its NexACT drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis and wound healing. For further information, go to www.nexmed.com and www.bio-quant.com
 
Taxol® is a registered trademark of Bristol-Myers Squibb Company

 

 

...bis zum 25.Januar wird/muss die Aktie die 1 USD-Marke geschafft haben, um nicht definitiv (zzgl.  ggf. extra "Verhandlung") von der Nasdaq ge-delistet zu werden.
Durch die Bio-Quant Aquisition ist NEOM >Dept-free!< - IMO ist die 1 USD-Marke keine Frage...

http://www.ariva.de/...KN_914164_NEXM_Nasdaq_t362738?page=0#jumppos24

...Also as previously announced, NexMed remains subject to a grace period through January 25, 2010 to evidence compliance with the $1.00 bid price requirement for continued listing on NASDAQ. ...

ein paar kilos zu 50cent gegönnt. mal schauen ob die 60cent halten.

gewechselt auf eine andere Firma mal schauen ob ich den Hattrick schaffe :)

termin 25.01 ist doch noch aktuell.

dank im vorraus

siehe: http://www.ariva.de/Las_Vegas_Sands_beobachten_t359358#jump7244376

von daher, mache deine DD selber (ich denke, man soll nur auf seine eigene ... hören?)

es ging mir um austauch von infos......? handeln werd ich nach eigenem ermessen ..
brauchst doch nicht gleich eingeschnappt sein :)
gruß doc

p.s werd heut nochmal nachlegen.

cu

aufgestockt zu 0,54 in 6 wochen könnt ihr sie dann für 1,2$ abkaufen :)

bin weg..

www.finanznachrichten.de/...proval-process-for-vitaros-004.htm

19.01.2010 20:02
NexMed Updates on Canadian Aproval Process for Vitaros

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, announced today that it received a Notice of Non-Compliance ("Notice") as part of the review process from Health Canada for its New Drug Submission ("NDS") for the Vitaros erectile dysfunction treatment filed in February 2008. The deficiencies cited related to the product's CMC (Chemistry, Manufacturing and Controls). There were no pre-clinical or clinical deficiencies cited in the Notice. The Notice is a routine end-of-review communication from Health Canada when additional information is needed to reach final decision on product approval.

Dr. Bassam Damaj, NexMed's Chief Executive Officer said, "The Notice provides us with a clear pathway to obtaining marketing approval of the product in Canada. The FDA had previously raised most of Health Canada's CMC issues and we were successful in working out a compliance plan with them. We look forward to discussing Health Canada's specific concerns in a face-to face meeting which will be our first since we filed the NDS. In the meantime, we remain optimistic about the approvability of our Vitaros product in Canada."

The normal process of follow up to the Notice is that NexMed has 90 days from the date of the Notice to respond to Health Canada, followed by the Health Canada 45 day screening process in the Regulatory Project Management group and then a 150 day review cycle by the NDS reviewers.

About NexMed

NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization ("CRO") based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed also has a proprietary product pipeline based on its NexACT drug delivery technology. For further information, go to www.nexmed.com and www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will successfully resolve the issues identified by Health Canada in the Notice or that Vitaros will receive marketing approval from Health Canada or other regulatory body.

Contacts:

NexMed:
NexMed, Inc.
Ed Cox, 858-926-5811
VP- IR
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


© 2010 Business Wire

translate.googleusercontent.com/...CNYkWJlvNxVde3q-faSAJ1V1ILA

...bin positioniert - es kann losgehen!

de.advfn.com/...chart&s=N^nexm&p=0&t=23&vol=1" style="max-width:560px" alt="" />

de.advfn.com/...chart&s=N^nexm&p=0&t=23&vol=1" style="max-width:560px" alt="" />

wenn ich das richtig gelesen habe schmeissen die sehr viele neue aktien auf denMarkt oder ?

 

siehe hier : 

 

ih.advfn.com/...4440958&article=41244053&symbol=N^NEXM

investorshub.advfn.com/boards/read_msg.aspx?message_id=45914978

Kannst Du mir deine eingefügte Meldung/Nachricht kurz übersetzen bzw. was dies
für Nexmed bedeutet ?

Besten dank im voraus.

Gruß und schönen Abend.

hm mein english ist glaube ich dafür dann doch zu schwach. verstehe da im Moment nur Bahnhof. Muss ich mir morgen in aller Ruhe mal zur Gemüte ziehen vlt. kann ich das besser verstehen als auf die schnelle.

 

Kleine Hilfestellung deinerseits könnte aber schon helfen. Wenn nicht auch nicht schlimm muss ich mich morgen mal durchbeissen

01.02.2010 20:36
www.finanznachrichten.de/...ontinued-listing-on-nasdaq-004.htm

NexMed Granted Request for Continued Listing on NASDAQ

Company Required to Hold Annual Meeting by May 24, 2010 and Evidence Bid Price of at Least $1.00 per share for Minimum of Ten Business Days by July 15, 2010

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that the NASDAQ Listing Qualifications Panel (the "Panel") has determined that NexMed has evidenced compliance with the market value of listed securities requirement for continued listing on The NASDAQ Capital Market by evidencing a market capitalization in excess of $35 million for a minimum of ten consecutive trading days, in lieu of the $2.5 million in stockholder's equity as required by the Panel's decision dated December 17, 2009. In its recent determination, the Panel also granted NexMed's request for an extension through May 24, 2010 to solicit proxies and hold its 2009/2010 Annual Meeting and thereby evidence compliance with NASDAQ's proxy solicitation and annual meeting requirements. In addition, the Panel has granted the Company's request for an extension through July 15, 2010 to evidence compliance with NASDAQ's minimum bid price requirement of $1.00 per share. On January 26, 2010, NexMed was notified by the NASDAQ Listing Qualifications Staff that the Company no longer satisfied the minimum bid price requirement. The Company was provided with the opportunity to present its plan to regain compliance with that requirement for the Panel's review and did so on January 27, 2010.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "We are very pleased with the Panel's decision to grant us the extension and we are committed to taking the actions needed to meet the remaining requirements for continued listing. The progress we have made with NASDAQ is the first step in executing our new growth strategy for 2010 and beyond."

About NexMed

NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed also has a proprietary product pipeline based on its NexACT® drug delivery technology. For further information, go to www.nexmed.com and www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, its ability to maintain its Nasdaq listing requirement and other matters that are outside the control of the Company.

Contacts:

NexMed Contacts:
NexMed, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


© 2010 Business Wire

translate.google.de/...ml%3Fx%3D0%26.v%3D1&sl=en&tl=de

08.02.2010 19:42
www.finanznachrichten.de/...-2-7-million-cash-infusion-004.htm

NexMed Receives over $2.7 Million Cash Infusion

Raises $2.3M through Private Placement of Promissory Notes and Receives $438,000 for the sale of its New Jersey State Net Operating Losses

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMed's option in either cash or shares of unregistered common stock at prices ranging from $0.36 to $0.40 per share. The private placement did not include any warrant or registration rights, therefore the investors are required to hold the securities for a minimum of six months. NexMed intends to use the proceeds raised from the transaction for general corporate purposes and to advance the applications of its NexACT delivery technology into the oral and biologics transdermal delivery space.

NexMed also announced the approval for the sale of its New Jersey state tax credits and net operating losses or NOLs pursuant to the Technology Tax Certificate Transfer Program sponsored by the state of New Jersey. The sale of these tax losses generates approximately $438,000 in net proceeds for NexMed.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "The completion of the private placement with two of our long-term shareholders at the announced terms is a direct reflection of their continued confidence in the strength of NexMed's proven pre-clinical service business, our technology and the value of our product pipeline, as well as our recent performance, including our ability to execute on our newly announced growth strategy while remaining NASDAQ listed. In the short time since NexMed's acquisition of Bio-Quant, our team has made solid progress toward developing additional, key indications for our current drug pipeline as well as in the discovery and validation of new uses for the NexACT drug delivery technology. As stated previously, we have also received multiple expressions of interest from biotechnology and pharmaceutical companies who may be interested in assessing the NexACT technology as a delivery mechanism for their own proprietary drug candidates. Going forward, we believe that the continued execution of our strategy, both financially and operationally, should allow us to achieve our goal of profitability in 2011."

About NexMed

NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed also has a proprietary product pipeline based on its NexACT® drug delivery technology. For further information, go to www.nexmed.com and www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, its ability to effectively implement its business strategy and become profitable in 2011 and other matters that are outside the control of the Company.

Contacts:

NexMed, Inc.
Edward Cox, 858-926-5811
ecox@nexmed.com
V.P. Investor Relations
or
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


© 2010 Business Wire

23.03.2010 18:22
www.finanznachrichten.de/...bution-agreement-for-japan-004.htm

NexMed, Inc. Enters into Distribution Agreement for Japan

NexMed, Inc. (Nasdaq: NEXM), a company with a revenue generating discovery pre-clinical CRO and a pipeline of products based on the NexACT® technology, today announced that its wholly-owned subsidiary, Bio-Quant has signed a distribution agreement with Cosmo Bio Co., Ltd, under which Cosmo Bio will market Bio-Quant's discovery and pre-clinical contract research services throughout Japan.

Based in Tokyo, Cosmo Bio is a well established distributor of life sciences products and services to academic researchers, biotechnology and pharmaceutical companies, specializing in oncology, inflammation, immunology and metabolic diseases.

Bassam Damaj, Ph.D., Chief Executive Officer of NexMed, stated, "With the third largest concentration of biotechnology and pharmaceutical companies in the world behind the U.S. and Europe, Japan represents a key growth opportunity for Bio-Quant. As such, we are very pleased to have solidified this partnership with Cosmo Bio. The distribution agreement provides us with a formal presence in Japan, where we have already established an initial foothold with a number of leading Japanese pharmaceutical companies. We look forward to working with the Cosmo Bio team as we further build our customer base, streamline incoming requests and provide centralized customer support."

About NexMed

Based in San Diego, California, NexMed's goal is to generate revenues from the growth of its discovery pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer.

For further information, go to www.nexmed.com and www.bio-quant.com.

Forward Looking Statement

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will be able to implement its growth strategy.

Contacts:

NexMed, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com



© 2010 Business Wire

24.03.2010 13:45
www.finanznachrichten.de/...al-results-conference-call-004.htm

NexMed Announces 2009 Fourth Quarter and Full Year Financial Results Conference Call

Conference Call/Webcast to be held Thursday, April 1, 2010 at 1:00 p.m. EDT

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today announced that management will hold a conference call to discuss 2009 fourth quarter and full year financial results and ongoing corporate activities, on Thursday, April 1, 2010 at 1:00 p.m. EDT. The Company will file its Form 10-K by the end of business on Wednesday, March 31, 2010.

The call can be accessed in the U.S. by dialing (877) 407-8031 and outside of the U.S. by dialing (201) 689-8031 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. (877) 660-6853 and outside of the U.S. by dialing (201) 612-7415. Replay pass codes 286 and 347666 are both required for playback. The conference call will also be Webcast live at www.investorcalendar.com/IC/CEPage.asp?ID=156852. The Webcast replay will be available for three months.

About NexMed

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed has embarked on a partnering program to pair the NexACT delivery technology with drugs and drug candidates marketed and being developed by others, including NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information, go to www.nexmed.com and www.bio-quant.com.

Contacts:

NexMed, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations & Corporate Development
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


© 2010 Business Wire

NexMed Files Investigational New Drug Application with FDA for Cancer Drug Candidate

Date : 03/29/2010 @ 11:06AM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)

ih.advfn.com/...9875217&article=42168793&symbol=N^NEXM

NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.

PrevOnco (the anti-ulcer compound, lansoprazole, approved under the name Prevacid® and marketed in the U.S. by Takeda Pharmaceuticals North America, Inc.) had been under development by FasTrack Pharmaceuticals, Inc. for the treatment of solid tumors, in particular, for the treatment of HCC. FasTrack received orphan Drug status for PrevOnco from the FDA in August 2008. In vitro and in vivo pre-clinical data generated to date has demonstrated the ability of lansoprazole to inhibit tumor cell growth and enhance survival in mouse models of cancer alone, and in combination with doxorubicin.

NexMed recently acquired PrevOnco from San Diego-based FasTrack Pharmaceuticals, which was spun out of Bio-Quant in October 2009; NexMed acquired Bio-Quant in December 2009. As an upfront payment, NexMed paid approximately $205,000 in the form of the cancellation of indebtedness owed by FasTrack to Bio-Quant. In addition, FasTrack and NexMed will share equally in any future revenues, including payments received from potential licensing partners, after first deducting NexMed’s future development expenses, including a 15% premium.

NexMed’s prospective, open label, single-arm, multicenter Phase II trial will assess the safety and efficacy of lansoprazole and doxorubicin in patients with advanced unresectable HCC at up to 10 study sites throughout the U.S. The primary objective of the study is to assess the response rate to doxorubicin and lansoprazole. Subjects will be treated with oral lansoprazole 90mg twice daily and intravenous (IV) doxorubicin 60 mg/m2 administered every 21 days. Subjects will continue to receive IV doxorubicin plus lansoprazole, if tolerated, up to a maximum of six consecutive cycles of doxorubicin, as long as there is no evidence of progressive disease. A total of between 15 and 70 subjects are expected to be enrolled in the study for a period of up to 12 months in the absence of disease progression or intolerance. Total study duration is anticipated to be one to three years, depending on the rate of enrollment and number of patients enrolled.

Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “Acquiring the rights to PrevOnco represents NexMed’s entrance into oncology and adds an important product candidate to our pipeline. With a solid safety profile, generated from over 15 years of human use of lansoprazol for the treatment of ulcers, and early indications of anti-cancer activity observed in pre-clinical studies, we believe that PrevOnco is a strong candidate for development with NexMed’s proprietary NexACT drug delivery technology as a second generation compound. Our recent filing of the IND with the FDA is a major milestone for NexMed, and we look forward to initiation of the Phase II trial.”

Dr. Ziad Mirza, Chief Executive Officer of FasTrack, stated, “We are excited to partner our company’s lead product candidate with NexMed. The expertise of Dr. Damaj and his team in the field of oncology will be invaluable in taking this program to the next level and we look forward to starting the pending Phase 2 trials.”

About Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is the seventh most common cancer in the world, with a higher incidence in China and other Asian countries. Although uncommon in the U.S., there are a reported 8,500 to 11,000 new cases diagnosed each year, comprising 2% of all malignancies. Cases in the U.S. occur primarily in men of Chinese descent, a subpopulation which has a relatively high incidence of viral hepatitis – a known risk factor for HCC.

About NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer.

About FasTrack Pharmaceuticals, Inc.

Based in San Diego, CA and founded in 2009, FasTrack Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutic drugs to treat life threatening diseases, including cancer and autoimmune diseases. The Company’s lead product candidate, PrevOnco, is under development for the treatment of various solid tumors.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including, but not limited to, the ability to successfully launch and complete the planned PrevOnco Phase II trial and the ability to reproduce pre-clinical findings in clinical trials.
posts are IMHO // eith

NexMed Announces Expansion of Its Bio-Quant Subsidiary Facilities

Date : 04/09/2010 @ 9:00AM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)

ih.advfn.com/...pid=nmona&article=42317233&symbol=NEXM

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today announced that it has expanded its San Diego facilities to accommodate an increase in demand for its pre-clinical research services. Bio-Quant now has approximately 28,000 sq. ft of modern, state-of-the-art laboratory, vivarium and office space.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “Our Bio-Quant business has experienced continuous growth during the past five years, including an increase of over 20% in revenues in 2009, alone. This has been achieved, in part, through a prior diversification of our service capabilities and entrance into new geographical markets. The ongoing expansion of our facilities is in response to the rising demand for the specialized services that we offer.”

About NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: www.nexmed.com or www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will be able to continue growing its CRO business.

NexMed and Ångstrom Pharmaceuticals to Present Data on Å6 Drug at AACR

Date : 04/13/2010 @ 11:00AM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)

ih.advfn.com/...d=nmona&cb=1271170984&article=42359149

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that Bio-Quant, its wholly-owned subsidiary, and Ångstrom Pharmaceuticals, a privately-held pharmaceutical company, will jointly present data at the 101st Annual Meeting of the American Association for Cancer Research (AACR), in Washington, D.C. from April 17-21, 2010. The poster presentation, entitled, “Å6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines in in vitro and in vivo studies,” covers pre-clinical work completed by Bio-Quant on Ångstrom’s lead product, Å6, currently in Phase 2 development for ovarian cancer.

Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, and one of the presenters at AACR, stated, “We are pleased to have supported Ångstrom in their target identification of the Å6 drug. Å6 has demonstrated activity in in vitro models of cell migration, invasion and angiogenesis, as well as in breast, prostate and brain tumor models. Similar activity was also seen in animal models of ocular disease. The results support the efficacy of Å6 across various cancer cells, which suggests that the drug is addressing a fundamental pathway for proliferative and invasive diseases.”

Malcolm Finlayson, Ph.D., President and Chief Executive Officer of Ångstrom, noted, “The work done by NexMed’s Bio-Quant team on behalf of Ångstrom is a testament to their expertise in the field of oncology. We look forward to the results of the ongoing studies on the mechanism of action of Å6.”

About Ångstrom Pharmaceuticals and Å6

Based in San Diego, CA, Ångstrom is developing a new class of drugs targeting CD44 for the treatment of diseases involving cell migration, invasion, and metastasis. Results from a completed Phase 1a safety clinical trial on Å6 showed there were no systemic drug-related adverse events in healthy volunteers. Ångstrom has also successfully completed a Phase 1b clinical trial evaluating Å6 in women with advanced gynecologic cancer, and a Phase 2 clinical trial evaluating Å6 in women with asymptomatic CA125 progression of epithelial ovarian cancer after first-line chemotherapy. Treatments were well tolerated and more than 40% of the patients dosed continuously with Å6 experienced disease stabilization. For further information, go to www.angstrominc.com.

About NexMed

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: www.nexmed.com or www.bio-quant.com.

www.investorvillage.com/...mp;mn=72&pt=msg&mid=8915228
the lion

www.thelion.com/bin/aio_msg.cgi?cmd=search&symbol=NEXM

das wär der hammer

Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “We are very pleased that the FDA agreed with our protocol for the HCC Phase 2 trial for PrevOnco™ as a first-line therapy for HCC. Additionally, we are actively assessing the suggestion made by the FDA to move directly into a Phase 3 trial, by studying PrevOnco™ in combination with Doxorubicin as a second-line therapy for patients who have failed NEXAVAR® therapy. Following this path could be very advantageous for NexMed since advancing the drug directly into a Phase 3 study would save us at least 12-24 months in development time.”

About Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is the seventh most common cancer in the world, with a high incidence in China and other Asian countries. Although uncommon in the U.S., there are a reported 8,500 to 11,000 new cases diagnosed each year, comprising 2% of all malignancies. Cases in the U.S. occur primarily in men of Chinese descent, a subpopulation which has a high incidence of viral hepatitis – a known risk factor for HCC.

About NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: www.nexmed.com or www.bio-quant.com.

habs bei den amis aufgeschnappt........

; )


Das sind echt gute Nachrichten für solch ein kleines Unternehmen mit nur 50 Mio. MK

www.nasdaq.com/aspxcontent/...px?selected=NEXM&mkttype=pre

kenn mich mit diesen pharmabuden nicht aus...dank im vorraus

jetzt kann sie auf 0,80 steigen ;)

die Amis legen wieder zu

Ich hoffe mal das die Bodenbildung bei 0,53$ war

close,,,,es wird mit mini size hoch und richtig fett volumen runter.....typischer abverkauf.
leider

ird wohl morgen weiter fallen......drecksaktie. werd die morgen shorten

Dr. Howell holds a number of patents for his innovative work in chemotherapeutics, drug-delivery systems, and diagnostic assays and is the recipient of numerous awards, including the Milken Family Medical Foundation Award for Outstanding Work in the Field of Cancer Research, a presidential citation from the American Head and Neck Society, and a Fogarty Senior International Fellowship. He is currently one of the main organizers of the American Association of Cancer Research.

Dr. Howell is a graduate of Harvard Medical School and is board certified in internal medicine and medical oncology. He completed his internship, residency, and medical oncology training at the Massachusetts General Hospital, the University of California, San Francisco, and the Dana Farber Cancer Institute, respectively. He completed his research training at the National Institutes of Health.


www.finance.yahoo.com/news/...-bw-3896121677.html?x=0&.v=1

sieht wieder gut aus ; )


www.nasdaq.com/aspxcontent/...px?selected=NEXM&mkttype=pre

werde short in diesem bereich schließen

baue morgen mein short aus....reine dillutation.
hoffe das hier keiner long ist :(

     Malcolm Finlayson, Ph.D., President und Chief Executive Officer von Ångstrom bemerkte: "Unsere Beziehung mit NexMed weiterhin in einem schnellen und Erfolg versprechenden Weg zu entwickeln. Diese neuen Daten ist sehr spannend und rechtfertigt weitere Untersuchungen, um die Möglichkeit, die Lizenz zu unterstützen NexACT® Technologie für klinische Versuche am Menschen. "

     Über Ångstrom Pharmaceuticals und A6.

     Mit Sitz in San Diego, CA, Ångström ist die Entwicklung einer neuen Klasse von Medikamenten, die an CD44 für die Behandlung von Erkrankungen, bei denen die Zellmigration, Invasion und Metastasierung. Die Ergebnisse einer abgeschlossenen Phase 1a Sicherheit klinischen Studie zeigte auf A6 gab es keine systemischen Medikamenten-Nebenwirkungen bei gesunden Probanden. Ångstrom hat sich auch erfolgreich eine Phase-1b-Studie zur Evaluierung der klinischen A6 bei Frauen mit fortgeschrittenem Krebs gynäkologischen abgeschlossen und eine klinische Phase-2-Studie zur Evaluierung A6 bei Frauen mit asymptomatischer CA125 Progression von epithelialen Ovarialkarzinom nach einer Erstlinien-Chemotherapie. Die Behandlungen wurden gut vertragen und mehr als 40% der Patienten permanent dosiert mit A6 erlebt eine Stabilisierung der Erkrankung. Für weitere Informationen gehen Sie zu www.angstrominc.com/

     Über NexMed, Inc.

     NexMed ist die größte Spezialität CRO Sitz in San Diego, CA und ist eine der branchenweit am meisten erfahrene CROs für die in vitro und in vivo Pharmakologie Dienstleistungen und Forschungsarbeiten Modelle. Ziel des Unternehmens ist es, die Einnahmen aus dem Wachstum seiner Discovery Vorklinische CRO Geschäft zu generieren, während aggressiv versucht, ihre proprietären NexACT ® Drug-Delivery-Technologie durch Out-Lizenzvereinbarungen mit monetize Pharma-und Biotechnologieunternehmen weltweit. Gleichzeitig ist NexMed aktiv Partnern für ihre NexACT® -Basierten Therapien für Onychomykose, Psoriasis, sexuelle Funktionsstörungen sowie Krebs. Für weitere Informationen über NexMed und ihre Tochtergesellschaften, besuchen Sie die folgenden Websites: www.nexmed.com oder www.bio-quant.com.

     Forward-Looking Statement Safe Harbor für NexMed

     Aussagen im Sinne des Private Securities Litigation Reform Act: Mit Ausnahme der historischen Informationen in dieser Pressemitteilung enthalten sind, die hier beschriebenen Inhalte enthalten vorausschauende Aussagen, die Risiken und Unsicherheiten, die einzeln oder gegenseitig beeinflussen könnten, die Dinge hier für eine Vielzahl von beschriebenen Gründen einbeziehen , die außerhalb des Einflussbereichs des Unternehmens, einschließlich, aber nicht ihre Fähigkeit begrenzt, aus der Lizenz-NexACT® Technologie, einschließlich der zu Angstrom, oder die NexACT® -Basierten Produkten in der Entwicklung. Darüber hinaus kann der vorklinischen Ergebnisse der Studie mit Tiermodellen menschlicher Erkrankungen nicht notwendigerweise indikativ für die Ergebnisse, die aus späteren klinischen Studien beim Menschen erwartet werden konnten.

     Kontakte:
     NexMed, Inc.
     Edward Cox, V.P.

     Investor Relations & Corporate Development NexMed, Inc.
     (858) 926-5811
     ecox@nexmed.com

     NexMed Investor Relations
     Paula Schwartz

     NexMed, Inc. Rx Communications Group, LLC
     (917) 322-2216
     pschwartz@rxir.com

     Ångstrom:
     Malcolm Finlayson, Ph.D., President und CEO

     Angstrom Pharmaceuticals, Inc.
     (858) 314-2356
     mfinlayson@angstrominc.com


www.nexmed.com/press_04282010.html

rest bleibt mit st 0,55 ;)

Pre-Clinical Results Show NexACT® Technology Significantly Improves Subcutaneous Delivery & Anti-Metastatic Activity of Angstrom Pharmaceuticals

Date : 04/28/2010 @ 6:47PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)

ih.advfn.com/...pid=nmona&article=42577837&symbol=NEXM

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, “These new findings, incorporating the NexACT-A6 peptide formulation, correlate with the half life and delivery profile of the Å6 compound from Angstrom’s previous studies using the higher dose. The positive results offer Ångstrom the potential to clinically test the NexACT-Å6 peptide at much higher doses while maintaining continuous coverage of the intended therapeutic target in human patients.” Dr. Damaj further added, “This study was NexMed’s first entry into the subcutaneous delivery of peptide drugs, and the results further confirmed the depot-like effect of the NexACT® technology which we had seen in our subcutaneous delivery studies with insulin and taxol.”

Malcolm Finlayson, Ph.D., President and Chief Executive Officer of Ångstrom noted, “Our relationship with NexMed continues to evolve in a fast and promising way. This new data is very exciting and warrants further investigation to support the opportunity to license the NexACT® technology for human clinical trials.”

About Ångstrom Pharmaceuticals and Å6

Based in San Diego, CA, Ångstrom is developing a new class of drugs targeting CD44 for the treatment of diseases involving cell migration, invasion, and metastasis. Results from a completed Phase 1a safety clinical trial on Å6 showed there were no systemic drug-related adverse events in healthy volunteers. Ångstrom has also successfully completed a Phase 1b clinical trial evaluating Å6 in women with advanced gynecologic cancer, and a Phase 2 clinical trial evaluating Å6 in women with asymptomatic CA125 progression of epithelial ovarian cancer after first-line chemotherapy. Treatments were well tolerated and more than 40% of the patients dosed continuously with Å6 experienced disease stabilization. For further information, go to www.angstrominc.com.

About NexMed

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT®-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: www.nexmed.com or www.bio-quant.com.

Forward-Looking Statement Safe Harbor for NexMed

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to out-license the NexACT® technology, including to Angstrom, or the NexACT®-based products under development. Additionally, pre-clinical study results involving animal models of human disease may not be indicative of the results that could be expected from subsequent clinical trials in humans.

05.05.2010 22:38
www.finanznachrichten.de/...wance-for-nexact-in-canada-004.htm

NexMed Announces Patent Allowance for NexACT® in Canada

NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Canadian Patent Office has issued a Notice of Allowance for NexMed's patent application entitled, "Crystalline Salts of Dodecyl 2-(N,N-Dimethylamino)-Propionate." This patent, when issued, will provide Canadian patent protection to May 2020, and is one in a series of patents and pending applications that NexMed owns on the NexACT technology and NexACT-based products under development.

Commenting on today's news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "The Company has a strong intellectual property position. In addition to the allowance in Canada, we have corresponding coverage and protection for our NexACT technology in the U.S. and other major markets. As we pursue our growth goals, we are aggressively seeking to expand the patent coverage for NexACT and to protect its potential for delivering new classes of drugs and/or via new routes of administration such as oral or subcutaneous delivery."

About NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: www.nexmed.com or www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to obtain and/or enforce patent coverage in major markets.

Contacts:

NexMed Contacts:
NexMed, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com



© 2010 Business Wire

www.finanznachrichten.de/...nt-of-key-industry-leaders-004.htm

06.05.2010 22:51
NexMed Expands Scientific Advisory Board with Appointment of Key Industry Leaders

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today announced the appointments of Jack A. Reynolds, Ph.D and Daniel R. Salomon, M.D., to its newly formed Scientific Advisory Board (SAB), expanding the SAB to four members.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, noted, "We are delighted to welcome Jack and Dan to our SAB. Our ability to recruit such key leaders in the scientific and medical industries is a testament to the strength of our technology and product pipeline. Both Jack and Dan are distinguished leaders in their respective fields. We look forward to benefiting from their guidance going forward."

Dr. Reynolds is currently Principal of JA Reynolds&Associates and General Managing Partner of Pharma Capital Partners, a private equity fund focused on the development of early-stage pharmaceutical assets. Dr. Reynolds spent a total of almost 18 years with the Pfizer Global Research and Development division, and over 30 years in the pharmaceutical industry. Until August 2006, he was Senior Vice President of Research and Development and Worldwide Head of Safety Sciences and Comparative Medicine. During his lengthy career, Dr. Reynolds has held leadership positions of increasing responsibility at Bristol-Myers Squibb, Bayer and Pfizer. He was also the Founding Director of the Center for Molecular Safety Sciences, a joint collaboration between the non-profit Hamner Center for Molecular Safety Sciences, Duke University and the University of North Carolina.

Dr. Salomon is currently medical director of the Center for Organ and Cell Transplantation for Scripps Health at Scripps Green Hospital and is an associate professor in the department of molecular and experimental medicine at The Scripps Research Institute. He currently serves as Chairman of the Tissue Engineering Committee for the American Society of Gene and Cell Therapy (ASGCT). Dr. Salomon's research interests include; the investigation of how molecular mechanisms driving immune cell activation and tissue injury are regulated at the gene transcriptional and proteomic level and mapping molecular networks that relate to clinical outcomes in cell and organ transplantation. Dr. Salomon previously held the position of chair of the U.S. Food and Drug Administration's Biological Response Modifiers Advisory Committee and has served on multiple NIH study sections and special emphasis panels for over 15 years.

About NexMed:

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed has embarked on a partnering program to pair the NexACT delivery technology with drugs and drug candidates marketed and being developed by others, including NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information, go to www.nexmed.com and www.bio-quant.com.

Contacts:

NexMed, Inc.
Edward Cox, V.P. Investor Relations
858-926-5811
ecox@nexmed.com
or
Rx Communications Group, LLC
Paula Schwartz, 917-322-1216
pschwartz@rxir.com



© 2010 Business Wire

guten morgen mein englisch ist aus den 80gern
könntes du in kurzen worten mal sagen was es neues giebt
jetzt schon mal danke uwe

das e welches ich zuviel geschrieben habe bitte überlesen!

www.stockhouse.com/News/USReleasesDetail.aspx

NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT(R) Technology to Enhance the Bioavailability of rituximab When Administered Subcutaneously NexMed Inc NEXM | 5/10/2010 5:19:02 PM SAN DIEGO, May 10, 2010 (BUSINESS WIRE) --  NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT(R) technology, today announced data from a pre-clinical study examining the subcutaneous delivery of rituximab, the first FDA-approved therapeutic antibody for the treatment of cancer in the United States. The study results showed that animals receiving subcutaneous injections of rituximab, incorporated with NexACT, demonstrated a 46% enhancement in bioavailability over rituximab, alone.  Rituximab is a cancer medication that interferes with the development of cancer cells, slowing their growth and spread in the body. Delivered via intravenous infusion, rituximab is the active drug in Rituxan(R), currently marketed by Genentech and Biogen IDEC, and prescribed to treat Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA).  Commenting on today's news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "The ability of the NexACT technology to successfully deliver rituximab subcutaneously in a pre-clinical setting may open the door to improving the delivery of other therapeutic antibodies, which the Company is in the process of studying. The use of human or humanized monoclonal antibodies, therapeutically, was a major breakthrough in the field of medicine. If the NexACT technology can ultimately be shown to lower the amount of antibody administered while improving the route of delivery and minimizing side effects, NexACT could potentially revolutionize the use of these drugs in the future. We look forward to advancing our work in this area and to the further studies that will be needed to validate these results in humans."  About NexMed, Inc.  NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.  Rituxan(R) is a registered trademark of Biogen IDEC.  Forward-Looking Statement Safe Harbor  Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to obtain and/or NexMed's ability to pursue its development strategy and the ability to replicate results from its preclinical research with the NexACT technology in later human clinical studies.

10.06.2010 19:32
www.finanznachrichten.de/...anadian-filing-for-vitaros-004.htm

NexMed Provides Update on Canadian Filing for Vitaros®

NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission ("NDS") with Health Canada for Vitaros®, the Company's topical treatment for erectile dysfunction.

NexMed management has been advised that Health Canada is continuing to review its response for acceptance, and the Company expects to hear from the agency within the next 30 days. An acceptance of the response by Health Canada will trigger a new, 150-day review cycle by the NDS reviewers for a final approval or rejection of the marketing application.

On April 23, 2010, NexMed reported that it had received delivery confirmation of its response to the CMC (Chemistry, Manufacturing and Controls) concerns previously raised by Health Canada (the "Response") related to its New Drug Submission for Vitaros, which was filed in February 2008. The delivery confirmation provided Health Canada with a 45-day screening for acceptance process of the Response by their Regulatory Project Management group, or until approximately June 4, 2010.

Management of NexMed also stated today that the Company is not currently selling shares of its common stock pursuant to the agreement with Brinson Patrick Securities Corporation. Further information concerning the agreement with Brinson is available pursuant to the Company's Form 10Q filed on May 13, 2010.

About NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: www.nexmed.com or www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that Health Canada will accept the Company's response for review or approve Vitaros for sale in Canada.

Contacts:

NexMed, Inc.
Ed Cox, 858-926-5811
V.P. Investor Relations
ecox@nexmed.com
or
NexMed Investor Relations
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com



© 2010 Business Wire

www.finanznachrichten.de/...s-bioequvalent-to-talconex-004.htm

15.06.2010 15:25
NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation is Bioequvalent to Talconex®

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

NexMed conducted two pre-clinical studies on its NexACT-based topical psoriasis treatment. The first efficacy study using a cadaver skin model showed that the NexACT-based formulation of the two active drugs delivered the same level of drugs (measured in ug/cm2/hour) as compared to the commercial Talconex® product. In a second efficacy study, using the DNFB induced allergic contact dermatitis (ACD) pig model, results showed that the NexACT-based formulation significantly lowered the clinical inflammation and erythema score in sick animals. The DNFB induced ACD pig model is the standard pre-clinical model for testing efficacy of calcipotriene-based drugs for psoriasis treatments under development.

Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, "We have a competitive psoriasis treatment under development. Our NexACT-based formulation is novel and does not infringe on the marketed topical treatments. Our data, though early stage, shows bioequivalency to Talconex®, and further supports the versatility of the NexACT technology and its applicability to a broad range of disease states. We look forward to commencing partnering discussions for continued development of this product candidate."


(...weiter siehe LINK)

Name Change to Apricus Biosciences - ( APRI )  
 
NexMed, Inc. Announces Results of Special Meeting of  Stockholders, Including Name Change to Apricus Biosciences
 
 Date : 09/10/2010 @ 4:31PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
 
http://ih.advfn.com/...pid=nmona&article=44327838&symbol=NEXM  
 
 NexMed, Inc. (Nasdaq:NEXM), backed by a revenue generating  CRO business and seeking to leverage its proprietary, multi-route  NexACT®  drug delivery technology and internal pipeline through  out-licensing arrangements and partnerships, announced the results of  its Special Meeting of Stockholders, held today, Friday, September 10,  2010.
 
At the Special Meeting, the Stockholders of the Company  approved, by an affirmative majority vote, to change the name of the  Company from NexMed, Inc. to Apricus Biosciences, Inc. (“Apricus Bio”),  effective September 10, 2010. The name change was brought on to reflect  the broader focus of the Company’s development programs. The  Company’s common stock will commence trading under the symbol, NASDAQ:  APRI, effective at the open of the market on Tuesday, September 14,  2010.
 
Dr. Bassam Damaj, President and Chief Executive  Officer of NexMed, commented, “Beginning with the acquisition of  Bio-Quant by NexMed in late 2009, we have undertaken a number of  positive changes that are expected to reshape the Company over the  long-term. In particular, we have expanded our product pipeline,  re-energized the development of the NexACT technology as a drug delivery  platform and have begun active licensing efforts for both proprietary  programs, as well as third party programs enhanced with the NexACT  technology. Additionally, we have leveraged Bio-Quant’s CRO capabilities  to help advance new applications for NexACT. The rebranding of the  Company at this time is part of our broader effort to alert potential  development partners and the investment community of our new business  model.”
 
In connection with the Company’s name change,  management expects to launch its new website, http://www.apricusbio.com  on Tuesday, September 14, 2010.
 
In addition, the  Stockholders approved, by an affirmative majority vote, to increase the number of shares of Common Stock  authorized for issuance by the Company from 18,000,000 shares to  75,000,000 shares.
 
About Apricus Biosciences
 
 Backed by a solid, revenue generating CRO business, Bio-Quant, Inc.,  and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility  of its proven NexACT® drug delivery technology to enable multi-route  administration of new and improved compounds across numerous therapeutic  classes. Future growth is expected to be driven primarily through  out-licensing of this technology for the development and  commercialization of such compounds to pharmaceutical and biotechnology  companies, worldwide. Concurrently, the Company is seeking to monetize  its existing product pipeline, including compounds from pre-clinical  through Phase 3, currently focused on dermatology, sexual dysfunction  and cancer. For further information on the Company and its subsidiaries,  visit http://www.nexmed.com.  

investorshub.advfn.com/boards/read_msg.aspx